Financials · MRKR

Marker Therapeutics Inc. (MRKR) financials

For the twelve months ended Mar 31, 2026, Marker Therapeutics Inc. reported $3.95M of revenue and -$10.90M of net income.

Revenue, TTM
$3.95M
Revenue growth, YoY
-30.7%
Net income, TTM
-$10.90M
Net margin
-275.9%
Cash
$11.33M
P/S
3.67
Market cap
$14.5M
Annual revenue$3.55M
FY2017FY2025
Annual net income-$12.16M
FY2016FY2025
Annual free cash flow-$18.66M
FY2017FY2019

MRKR revenue and earnings growth

MRKR revenueQ1 2026$751.7K

Quarter YoY
+115.3%
QoQ
-31.9%
FY YoY
-46.2%
5Y CAGR
+48.0%

MRKR revenue was $751.7K in fiscal Q1 2026 (ended Mar 31, 2026), up 115.3% from a year earlier and down 31.9% from the prior quarter. For the full fiscal 2025 it was $3.55M, down 46.2% from fiscal 2024. Compound annual growth was +48.0% over 5 years. It rose in 6 of the last 8 fiscal years.

MRKR net incomeQ2 2026-$1.83M

MRKR net income was -$1.83M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.02M a year earlier. For the full fiscal 2025 it was -$12.16M, compared with -$10.73M in fiscal 2024.

MRKR EPSQ2 2026-$0.09

MRKR diluted EPS was -$0.09 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.29 a year earlier. For the full fiscal 2025 it was -$0.79.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$3.55M$6.59M$3.31M$3.51M$1.24M$500.0K$213.2K$206.0K$183.1K-
Research and development$11.80M$13.47M$10.42M$11.97M$27.79M$18.88M$12.76M$7.95M$5.25M$3.80M
Selling, general and admin$4.18M$4.24M$7.48M$11.34M$12.92M$10.47M$9.98M$24.38M$6.41M$4.69M
Operating income-$12.89M-$11.12M-$14.58M-$19.79M-$39.48M-$28.89M-$22.53M-$148.17M-$11.48M-$8.49M
Pre-tax income-$12.18M-$10.68M-$14.04M-$19.78M------
Income tax-$15.2K$50.0K$3.7K----$0$0$0
Net income-$12.16M-$10.73M-$8.24M-$29.93M-$41.88M-$28.71M-$21.43M-$147.96M-$10.98M-$2.46M
EPS, basic-$0.79-$1.19-$0.94-$3.58-$5.47-$6.10-$4.70-$77.50-$11.60-$3.60
EPS, diluted-$0.79-$1.19-$0.94-$3.58-$5.47-$6.10-$4.70-$77.50-$11.60-$7.20
Diluted shares15.3M9.0M8.8M8.4M7.7M4.7M4.6M1.9M945,348.3742,099.5

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$16.07M$19.19M$15.11M$11.78M$43.50M$21.35M$43.90M$61.75M$5.13M$7.85M
Current assets$19.07M$22.02M$17.13M$16.62M$45.98M$24.41M$45.49M$62.00M$5.18M$7.92M
Total assets$19.07M$22.02M$17.13M$34.42M$68.14M$45.61M$46.36M$62.14M$5.18M$7.92M
Current liabilities$2.27M$3.46M$3.07M$7.78M$12.90M$6.40M$1.99M$2.80M$1.52M$1.74M
Total liabilities$2.27M$3.46M$3.07M$14.82M$24.15M$18.27M$2.27M$2.80M$1.52M$1.74M
Shareholders' equity$16.80M$18.56M$14.05M$19.60M$43.99M$27.34M$44.09M$59.34M$3.66M$6.18M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$12.01M-$10.91M-$16.44M-$26.97M-$27.28M-$20.03M-$18.28M-$14.48M-$8.44M-$6.51M
Capital expenditures------$375.0K$147.7K$0-
Free cash flow-------$18.66M-$14.63M-$8.44M-
Investing cash flow--$18.66M-$4.95M-$3.13M-$9.25M-$375.0K-$147.7K$0-
Financing cash flow$9.86M$14.99M$1.11M$202.1K$52.56M$6.74M$816.5K$71.25M$5.72M$7.78M
Share repurchases-------$71.7K$310.5K$0
Stock-based compensation$537.5K$245.9K$858.3K$3.30M$5.96M$5.23M$5.36M$16.35M$2.74M$1.56M
Depreciation and amortization---$2.79M$2.15M$485.6K$105.1K---

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY-46.2%99.1%-5.8%183.0%148.3%134.5%3.5%12.5%--
Operating margin-363.5%-168.7%-440.4%-563.3%-3179.3%-5777.2%-10567.3%-71930.1%-6271.1%-
Net margin-343.0%-162.8%-248.8%-851.9%-3372.7%-5741.2%-10050.9%-71826.3%-5999.1%-
Free cash flow margin-------8752.3%-7101.0%-4610.1%-
Return on equity-72.4%-57.8%-58.6%-152.7%-95.2%-105.0%-48.6%-249.3%-300.2%-39.7%
Return on assets-63.8%-48.7%-48.1%-87.0%-61.5%-62.9%-46.2%-238.1%-212.0%-31.0%
Current ratio8.396.365.572.143.563.8122.8322.113.404.56

Source: XBRL data Marker Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Nov 4, 2016; 1-for-10, first reported Mar 22, 2023.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

MRKR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
MRKR$3.95M-30.7%-$10.90M-275.9%$14.5M
ATRA$3.96M-97.4%-$14.61M-368.6%$78.5M
IOVA$378.98M+51.3%-$220.53M-58.2%$3.59B
CELU$18.67M-58.1%-$45.86M-245.7%$20.5M

MRKR FAQ

6 questions
  • What is MRKR revenue?
    Marker Therapeutics Inc. (MRKR) reported $3.95M of revenue for the twelve months ended Mar 31, 2026. That is down 30.7% from the year before. Revenue for fiscal 2025 was $3.55M.
  • Is MRKR profitable?
    No. Marker Therapeutics Inc. reported a net loss of $10.90M for the twelve months ended Mar 31, 2026.
  • How much cash and debt does MRKR have?
    Marker Therapeutics Inc. reported $11.33M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is MRKR revenue growing?
    Marker Therapeutics Inc.'s revenue changed -46.2% in fiscal 2025, to $3.55M. Its compound annual growth rate was +48.0% over 5 years.
  • When did MRKR last report financial results?
    The latest statements here come from Marker Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this MRKR financial data come from?
    Quantisnow builds these statements from the structured XBRL data Marker Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.